Several pharma companies have told investors of potential earnings drops caused by the looming implementation of drug pricing reform in the US. This includes companies like Merck, Amgen, Eli Lilly, and more, some of which blamed decisions to cut back on research. The drug reform law in the […]
US Democrats Eye Drug Launch Prices
With a recent legislative win in the books with drug pricing reform in the Inflation Reduction Act, Democrats are looking towards high drug launch prices. In recent years, the launch prices of many drugs, especially biologics, have skyrocketed, with the average launch price in 2021 at […]
Global Pricing Innovations Launches GPI Horizon Platform for Value Assessment
Global Pricing Innovations (GPI) has announced the launch of its new GPI Horizon platform. GPI Horizon is an analytics-based tool to expedite value-assessment and price prediction across the entire life cycle to help drive market access and reduce payer risk. The program is part of GPI’s larger […]
Proving the Value of Real-World Data to Stakeholders
As more and more pharma companies, payer groups, and regulatory bodies accept the growing use of real-world data (RWD) in decision-making, it is becoming ever more important to demonstrate the resource’s value to stakeholders. In a new article by Barbara Arone MS, VP of Real World Solutions at […]
India’s NPPA to Reconsider Retail Price Fixing for Cipla’s Combo Inhaler
India’s National Pharmaceutical Pricing Authority (NPPA) has been told by the Department of Pharmaceuticals (DoP) to consider Cipla’s retail pricing application for a combination inhaler drug. The decision comes after years of legal struggles surrounding similarities between the drug, a combination […]
Teva Agrees to Pay New York $523 Million
Teva Pharmaceuticals has agreed to settle yet another case relating to its role in the US opioid crisis, this time with the state of New York. According to the state’s Attorney General Tish James, the pharma giant will pay an additional $313 million on top of the $210 million the state will receive […]
McKesson Reaches $141 Million Settlement with Shareholders in Generic Price Fixing Lawsuit
McKesson Corp. has indicated it reached a settlement with shareholders to the tune of $141 million in a lawsuit over price fixing claims regarding generic medications. The plaintiffs argued that the company lied when it said that it was raising prices due to supply disruptions, instead doing so for […]
Indian Pharma Industry Fares Well Amid Inflation and Pricing Concerns
An ICRA analysis of 16 leading Indian pharma companies finds the industry doing well in spite of concerns regarding inflation and drug pricing. The selected companies reported an average revenue growth of 4.9%, driven in part by market growth in the US and abroad. However, the report also noted a […]
Norstella and Citeline Announce Complete Merger
Norstella, a biotech that provides end-to-end services for therapeutic development has merged with Citeline, a leader in pharma intelligence. The acquisition brings the value of Norstella up to $5 billion, ranking among the largest in the industry. Norstella will use Citeline’s range of services and […]
Eli Lilly and US HHS at Odds Over 340B Program in Federal Court
The US Department of Health and Human Services (HHS) and Eli Lilly butted heads in a recent federal appeals court hearing over the agency’s 340B drug discount program, which requires that drugmakers give discounts on certain drugs to pharmacies that serve underprivileged communities. Lilly has […]
